Aspirin in the treatment and prevention of cardiovascular disease

Annual Review of Public Health

Volumn 18, Issue , 1997, Pages 37-49

  Hennekens, Charles H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

antiplatelet therapy; myocardial infarction; occlusive vascular disease; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA CAROTENE; DIPYRIDAMOLE; PLACEBO; PROSTACYCLIN; STREPTOKINASE; SULFINPYRAZONE; THROMBOXANE A2; THROMBOXANE B2;

ANGINA PECTORIS; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEATH; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEARTBURN; HUMAN; INDIGESTION; META ANALYSIS; NAUSEA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0030935637     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.18.1.37     Document Type: Review

References (31)

1. Antiplatelet Trialists' Collaboration. 1988. Secondary prevention of vascular disease by prolonged anti-platelet therapy. Br. Med. J. 296:320-32
2. Antiplatelet Trialists' Collaboration. 1994. Collaborative overview of randomized trials of antiplatelet treatment. Part I: prevention of vascular death, myocardial infarction and stroke by prolonged antiplatelet therapy in different categories of patients. Br. Med. J. 308:81-106
3. Aspirin for TIA's. 1980. FDA Drug Bull. 10:2-5
4. Aspirin for heart patients. 1985. FDA Drug Bull. 15:34-36
5. Boston Collaborative Drug Surveillance Group. 1974. Regular aspirin intake and acute myocardial infarction. Br. Med. J. 1:440-43
6. Buring JE, Hennekens CH, for the Women's Health Study Research Group. 1992. The Women's Health Study: summary of the study design. J. Myocard. Ischemia 4:27-29
7. Buring JE, Hennekens CH, for the Women's Health Study Research Group. 1992. The Women's Health Study: rationale and background. J. Myocard. Ischemia 4:30-40
8. Clarke RJ, Mayo G, Price P, FitzGerald GA. 1991. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Wed. 325:1137-41
9. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, et al. 1990. Blood pressure, stroke and coronary heart disease. Part II: effects of short-term reductions in blood pressure - an overview of randomised drug trials in an epidemiological context. Lancet 335:827-38
10. Fuster V, Dyken ML, Vokonas PS, Hennekens CH. 1993. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 87:659-75
11. Hammond EC, Garfinkel L. 1975. Aspirin and coronary heart disease: findings of a prospective study. Br. Med. J. 2:269-71
12. Hennekens CH, Buring JE. 1987. Epidemiology in Medicine. Boston: Little, Brown & Co.
13. Hennekens CH, Buring JE, Mayrent S. 1984. Smoking, aging and coronary heart disease. In Smoking and Aging, ed. R Bosse, Lexington, MA: Heath
14. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. 1989. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80:749-756
15. Hennekens CH, Eberlein K. 1985. A randomized trial of aspirin and beta-carotene among US physicians. Prev. Med. 14:165-68
16. Hennekens CH, Jonas MA, Buring JE. 1994. The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the US Arch. Int. Med. 1:37-39
17. Hennekens CH, Karlson LK, Rosner B. 1978. A case control study of regular aspirin use and coronary deaths. Circulation 58:35-38
18. Hennekens CH, Peto R, Hutchison GB, Doll R. 1988. An overview of the British and American aspirin studies. N. Engl. J. Med. 318:923-24
19. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349-60
20. Jick H, Miettinen OS. 1976. Regular aspirin use and myocardial infarction. Br. Med. J. 1:1057
21. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. 1992. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N. Engl. J. Med. 327:241-47
22. Manson JE, Grobbee DE, Stampfer MJ, Taylor JO, Goldhaber SZ, et al. 1990. Aspirin in the primary prevention of angina pectoris in a randomized trial of US physicians. Am. J. Med. 89:772-76
23. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, et al. 1991. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 266:521-27
24. Moncada S, Vane JR. 1979. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N. Engl. J. Med. 300:1142-47
25. Paganini-Hill A, Chao A, Ross RK, Henderson BE. 1989. Aspirin use and chronic diseases: a cohort of the elderly. Br. Med. J. 299:1247-50
26. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, et al. 1988. A randomised trial of the effects of prophylactic daily aspirin among male British doctors. Br. Med. J. 296:313-16
27. Peto R, Yusuf S, Collins R. 1985. Cholesterol-lowering trial results in their epidemiologic context. Circulation 72(Suppl. III):451
28. Steering Committee of the Physicians' Health Study Research Group. 1989. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321:129-35
29. UK-TIA Study Group. 1988. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial interim results. Br. Med. J. 296:316-320
30. US Food and Drug Administration. 1996. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Proposed amendment to the tentative final monograph. Federal Register 1996 61:30002. (June 13, 1996)
31. US Preventive Services Task Force. 1996. Aspirin prophylaxis for the primary prevention of myocardial infarction. In Guide ta Clinical Preventive Services. Baltimore, MD: Williams & Wilkins. 2nd ed.